March 20, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

Size: px
Start display at page:

Download "March 20, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852"

Transcription

1 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C Tel: Fax: March 20, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD Re: Docket No. FDA-2016-D-4412; Draft Guidance for Industry: Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA The Advanced Medical Technology Association ( AdvaMed ) appreciates the opportunity to provide comment on the Food and Drug Administration s ( FDA or Agency ) Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA. AdvaMed represents manufacturers of medical devices, diagnostic products, and health information systems that are transforming health care through earlier disease detection, less invasive procedures, and more effective treatment. Our members range from the smallest to the largest medical technology innovators and companies, including manufacturers of combination products that include a drug and a delivery device intended to administer a drug product. We are concerned that this draft guidance proposes an approach that is inconsistent with the Center for Devices and Radiological Health ( CDRH ) Guidance for Industry and Food and Drug Administration Staff: Applying Human Factors ( HF ) and Usability Engineering to Medical Devices (February 3, 2016) (hereinafter 2016 CDRH HF guidance ) and does not appropriately factor in risk-based approaches. The ultimate goal of usability engineering is to ensure the usability and use-safety of the product as assessed through critical tasks analysis, formative/summative usability studies and use-related risk analysis. This draft guidance frequently discusses methods that are similar, but meaningfully different (e.g., comparing "critical external design attributes" and non-inferiority HF studies). Modest changes to the language and suggested study designs in this draft guidance could enable the methodology to be aligned with other FDA HF guidances and recognized standards, while also ensuring the generic product is interchangeable with the reference from a usability perspective and safe for users. The February 2016 CDRH HF guidance describes the use of critical task assessment, and formative and summative HF studies in conjunction with appropriate risk analyses, as the route to determine usability and use-safety. The root cause for use errors with the CDRH guidancesuggested sample size along with subjective feedback are analyzed in the context of use-related risk to determine if the observed errors (or pattern of errors) results in unacceptable risk. This same approach should be used to evaluate a proposed generic product relative to its reference product. The same type of summative study can be executed to evaluate differences in a UI to evaluate for both products whether any use errors, considering their root cause and associated Bringing innovation to patient care worldwide

2 Docket No. FDA-2016-D-4412 March 20, 2017 Page 2 of 2 risks, result in unacceptable harm (noting the assumption that the residual risk for the reference product is acceptable). A non-inferiority study, as proposed in the Draft Guidance, reduces use errors to solely a statistical assessment, which is contradictory to other guidances and standards. Moreover, many differences in the UI may not be "external design attributes," but internal product design choices that impact product functionality (e.g., spring force of an Auto-injector impacting injection time). Recrafting the language to be more consistent with other HF guidances in terms of the impact of the user interface on critical tasks and the associated risks will improve clarity. Attachment A provides specific comments on the Draft Guidance. The comments suggest wording changes that would provide clarification and request clarification when the intent of the text is unclear. We have provided a line-numbered copy of the language of the Draft Guidance. We appreciate the efforts taken by FDA personnel in preparing this Draft Guidance and support the goals of developing a Guidance that serves the mission of FDA, the needs of industry and the common goal of benefiting public health. AdvaMed would like to thank the FDA for its consideration of these comments. Please do not hesitate to contact me at or jelder@advamed.org if you have any questions. Respectfully submitted, /s/ Jordan Elder Associate Vice President Technology and Regulatory Affairs

3 AdvaMed Comments Draft Guidance for Industry: Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA Docket No. FDA-2016-D-4412 Line Number General General General 30, 34, 157, etc Guidance Text Proposed Change Comment/Rationale The February 2016 CDRH HF guidance describes the use of critical task assessment, and formative and summative HF studies in conjunction with appropriate risk analyses as the route for determine usability and use-safety. The root cause for use errors with the CDRH guidance-suggested sample size along with subjective feedback are analyzed in the context of use-related risk to determine if the observed errors (or pattern of errors) results in unacceptable risk. This same approach can be used to evaluate a proposed generic product relative to its reference product. The same type of summative study can be executed to evaluate differences in a UI to evaluate for both products whether any use errors, considering their root cause and associated risks, results in unacceptable harm (noting the assumption that the residual risk for the reference product is acceptable). A non-inferiority study, as proposed in the guidance, reduces use errors to solely a statistical assessment, which is contradictory to other guidances and standards. We are concerned that this draft guidance proposes an approach that is inconsistent with the CDRH Human Factors guidance and does not appropriately factor in the risk-based approaches. The ultimate goal of usability engineering is to ensure the usability and use-safety of the product as assessed through critical tasks analysis, formative/summative usability studies and use-related risk analysis. This guidance frequently discusses methods that are similar but meaningfully different (e.g., comparing "critical external design attributes" and non-inferiority HF studies). Modest changes to the language and suggested study designs in this guidance could enable the methodology to be aligned with and consistent to, other FDA Human Factors guidances and recognized standards, while also ensuring the generic is interchangeable with the reference from a usability perspective and safe for users. Many differences in the UI may not be "external design attributes", but internal product design choices that impact product functionality (e.g., spring force of an Auto-injector impacting injection time). Recrafting the language to be more consistent with other HF guidances in terms of the impact of the user interface on critical tasks and the associated risks will improve clarity. " conduct threshold analysis " " conduct comparative analysis " Comparative analysis describes the analysis more clearly. " difference in device and labeling " Add sentence to the end of the scope section. "differences in device, packaging and labeling " This guidance is not intended to address the HF work needed to assess sponsorinitiated modifications to a commercial combination product. Human factors activities needed to support this type of product change are discussed in Section 8.2 of the 2016 CDRH HF guidance. Page 1 of 5 Packaging is part of the product UI and should be included. The Agency may also wish to consider addressing training material. This is an important detail needed in the product scope. A sponsor may easily incorrectly interpret this guidance as being relevant for post-approval changes to marketed products.

4 This section provides more detail than necessary describing what is needed for an Abbreviated New Drug Application in the Chemistry Manufacturing Controls section. "This section discusses support the design of the user interface of the proposed generic." End this section at the end of the sentence in line 105 and provide a reference to appropriate guidances. "This section discusses support assessment of the usability and use safety of the proposed generic..." To clarify the text "the overall design of the user interface and should generally seek approval of a presentation approved for the RLD." "FDA may accept such design differences if they are adequately analyzed, scientifically justified and do not preclude approval in an ANDA..." "To conduct a comparative analysis of the user interface of the proposed generic combination product and its RLD, potential applicants should examine, among other things, the external critical design attributes of the proposed delivery device " "the overall design of the user interface and should generally seek approval of a presentation as similar as possible to the RLD." "FDA may accept such design differences if they are adequately analyzed, scientifically justified and result in acceptable residual risk related to the usability and use safety of the product." "To conduct a comparative analysis of the user interface of the proposed generic combination product and its RLD, potential applicants should examine, among other things, the critical product use tasks and design attributes of the product that could impact the user's ability to perform these tasks safely and effectively " To clarify the text. The acceptability of design differences from an HF perspective should be based on the acceptability of residual risks related to the usability and use safety of the product. Other CMC or clinical aspects of the product are out of scope for this guidance. The term "external critical design attributes" and associated analysis may be unclear to sponsors and redundant to analyses typically performed as part of established risk management (per ISO 14971) and usability engineering processes (ISO 62366, CDRH HF guidance) where the differences between the products are determined and their potential to impact usability and use safety is assessed through a risk analysis (e.g., a use-related failure modes and effects analysis). This risk analysis will be performed as part of product development, and it is suggested that this be leveraged for the purposes of the comparative analysis and assessment of acceptable risk. The need to conduct human factors validation should be based on the risk analysis of the differences in the UI and focus on the hazardrelated use scenarios and critical tasks. Page 2 of 5

5 "external critical design attributes are those." "as a result, there is concern that patients or caregivers who encounter different user interfaces, such as differences in external critical design attributes, may be at increased risk" Remove prescribing information from the list or consider rewording to note aspects of the prescribing information that impact usability and use safety. "If differences are identified between the design of the user interface of the proposed generic combination product and the user interface of its RLD, the sponsor should focus on whether the difference involves an external critical design attribute that may potentially impact..." Where differences between the generic and the RLD have the potential to impact the user's ability to perform a critical task, applicants should analyze these differences in the context of a userelated risk analysis (e.g., use-related failure modes and effects analysis) to assess the level of risk. Risks should be reduced where possible by design since users experienced with the generic products are unlikely to be retrained or read the instructional material upon receiving the generic. "as a result, there is concern that patients or caregivers who encounter different user interfaces, especially if they impact their ability to perform critical tasks, may be at increased risk " N/A "If differences are identified between the design of the user interface of the proposed generic combination product and the user interface of its RLD, the sponsor should focus on whether the difference may impact a critical task, hence the usability and use safety of the product. A risk analysis consistent with ISO and 2016 CDRH HF guidance is suggested as well as an assessment of the product residual risk " As noted in the previous line, a risk analysis is the industry standard tool for assessing design, process and use-related risks. Notably, these tools are used when sponsors make product changes to assess the impact of a change on safe and effective use and can be used similarly here. This approach will ensure analysis consistency with the risk management process applicants follow for other aspects of product development. Revised to recognize that the acceptability of different user interfaces will come back to whether they will affect the ability to perform critical tasks. Most of the PI content is outside the scope of human factors and the usability and use safety of the product. The acceptability of the differences in the product User Interfaces should come back to critical tasks and an analysis of acceptable risk. Page 3 of 5

6 FDA views the impact of a design difference to be minor if the differences in the user interface of the proposed generic combination product, in comparison to the user interface of the RLD, does not affect an external critical design attribute. Other design differences: FDA may not view a design difference as minor if any aspect of the threshold analysis suggests that differences in the design of the user interface of a proposed generic combination product as compared to the RLD may impact an external critical design attribute that involves administration of the product "the objective of the comparative use human factors studies described in this guidance is to demonstrate that the use error rate, associated with the change in an external critical design attribute for the proposed user interface, does not preclude approval of the proposed product in an ANDA" We suggest removing the proposed non-inferiority study design. FDA views the impact of a design difference to be minor if the differences in the user interface of the proposed generic combination product, in comparison to the user interface of the RLD, do not affect the ability of the user to perform critical tasks. Other design differences: FDA may not view a design difference as minor if any aspect of the comparative analysis suggests that differences in the design of the user interface of a proposed generic combination product as compared to the RLD, may impact the user's ability to perform critical tasks. "the objective of the comparative use human factors studies described in this guidance is to demonstrate that the residual risk related to use errors associated with the generic do not preclude approval of the proposed product in an ANDA" A comparative use human factors study should be designed to provide sufficient data that the proposed generic product can be used with no increase in risk to usability and use safety as compared to the RLD when analyzed in the context of a risk assessment. The acceptability of the differences should come back to critical tasks and an analysis of acceptable risk. The acceptability of the differences should come back to critical tasks and an analysis of acceptable risk. We would recommend not calculating use error rates, but focusing on the root cause of observed errors and associated risks. Consistency with 2016 CDRH HF guidance. We would propose one of the following two options: Option 1: One study design could be considered where the sponsor evaluates Page 4 of 5

7 differences in the generic product user interface to demonstrate that no use errors result in unacceptable use-related risks. The sponsor should consider testing both users experienced with the RLD as well as naive users. Option 2: A second study design option can be implemented where the sponsor evaluates the differences between the generic product and RLD user interfaces by testing those differences with users first using the RLD and then the proposed generic product. This approach would demonstrate whether differences between the two products would preclude switching from one product to the other without retraining. For either study design, and per FDA s 2016 CDRH HF guidance, root cause analysis for any user errors, close calls and use difficulties should be performed. Additionally, "the root cause of all use errors and problems should then be considered in relation to the associated risks to ascertain the potential for resulting harm" (8.1.6 CDRH HF guidance) and determine where the residual risk is acceptable or whether additional risk control measures need to be implemented. Study designs and sample sizes should be consistent with the aforementioned guidances and consensus standards (e.g., Appendix B 2016 CDRH HF guidance). Page 5 of 5

Docket No. FDA-2017-D-0154: Considerations in Demonstrating Interchangeability with a Reference Product

Docket No. FDA-2017-D-0154: Considerations in Demonstrating Interchangeability with a Reference Product 1227 25th St. NW #700 Washington, DC 20037 combinationproducts.com 202.861.1881 FDA-2017-D-0154 VIA ELECTRONIC SUBMISSION May 19, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration

More information

September 26, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

September 26, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers

More information

April 28, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

April 28, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers

More information

In addition, below we offer our responses to the questions posed in the Federal Register Notice announcing the availability of the Draft Guidance:

In addition, below we offer our responses to the questions posed in the Federal Register Notice announcing the availability of the Draft Guidance: 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org September 24, 2015 Division of Dockets Management (HFA305) Food and Drug Administration

More information

Biotechnology Industry Organization 1225 Eye Street NW, Suite 400 Washington, DC 20006

Biotechnology Industry Organization 1225 Eye Street NW, Suite 400 Washington, DC 20006 Biotechnology Industry Organization 1225 Eye Street NW, Suite 400 Washington, DC 20006 December 22, 2003 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville,

More information

I. The Medical Technology Industry s Cybersecurity Efforts and Requirements

I. The Medical Technology Industry s Cybersecurity Efforts and Requirements 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org June 12, 2018 U.S. House of Representatives Committee on Energy and Commerce 2125 Rayburn

More information

Human Factors Usability in the Review of New Medical Devices FDA/CDRH. Considering Usability for Pharmaceutical Aerosol Devices.

Human Factors Usability in the Review of New Medical Devices FDA/CDRH. Considering Usability for Pharmaceutical Aerosol Devices. Human Factors Usability in the Review of New Medical Devices FDA/CDRH Considering Usability for Pharmaceutical Aerosol Devices Ron Kaye Human Factors Pre-Market Evaluation Team Leader Office of Device

More information

Center for Devices and Radiological Health Premarket Approval Application Critical to Quality

Center for Devices and Radiological Health Premarket Approval Application Critical to Quality This document is scheduled to be published in the Federal Register on 09/12/2017 and available online at https://federalregister.gov/d/2017-19258, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

The Human Touch: Develop a Patient-Centric Injection Device

The Human Touch: Develop a Patient-Centric Injection Device The Human Touch: Develop a Patient-Centric Injection Device Molly Story, PhD 27 September 2017 Photo credits: Why should we care about being patient-centric? The FDA tells us: Our drugs must be safe and

More information

April 21, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

April 21, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061

More information

Global Unique Device Identification Database (GUDID); Draft Guidance

Global Unique Device Identification Database (GUDID); Draft Guidance One Boston Scientific Place Natick, MA 01760 (508) 652-7400 Tel (508) 652-1898 Fax www.bostonscientific.com November 25, 2013 Divisions of Docket Management (HFA-305) Food and Drug Administration 5630

More information

FDA-2008-N-0424 VIA ELECTRONIC SUBMISSION. June 18, 2018

FDA-2008-N-0424 VIA ELECTRONIC SUBMISSION. June 18, 2018 1227 25th St. NW #700 Washington, DC 20037 combinationproducts.com 202.861.4199 FDA-2008-N-0424 VIA ELECTRONIC SUBMISSION June 18, 2018 Dockets Management Staff (HFA-305) Food and Drug Administration 5630

More information

FDA & Medical Device Cybersecurity

FDA & Medical Device Cybersecurity FDA & Medical Device Cybersecurity Closing Keynote, February 19, 2017 Suzanne B. Schwartz, M.D., MBA Associate Director for Science & Strategic Partnerships Center for Devices and Radiological Health US

More information

NRC INSPECTION MANUAL MANUAL CHAPTER 0609

NRC INSPECTION MANUAL MANUAL CHAPTER 0609 NRC INSPECTION MANUAL MANUAL CHAPTER 0609 IPAB SIGNIFICANCE DETERMINATION PROCESS 0609-01 PURPOSE The Significance Determination Process (SDP) uses risk insights, where appropriate, to help NRC inspectors

More information

April 21, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, Maryland 20852

April 21, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, Maryland 20852 April 21, 2016 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, Maryland 20852 RE: Comments of ACT The App Association regarding the Food and

More information

Below we ve highlighted several of the key points from the final guidance document.

Below we ve highlighted several of the key points from the final guidance document. On September 6, 2017, the Food and Drug Administration (FDA or the Agency) released its final guidance document, Design Considerations and Pre-Market Submission Recommendations for Interoperable Medical

More information

Re: ENERGY STAR Telephony Draft 2 Version 3.0 Telephony Test Method and Data Call

Re: ENERGY STAR Telephony Draft 2 Version 3.0 Telephony Test Method and Data Call December 28, 2012 Mr. Paul Karaffa ENERGY STAR Product Development U.S. Environmental Protection Agency Energy Star for Office Equipment 1200 Pennsylvania Avenue, N.W. Washington, DC 20460 Re: ENERGY STAR

More information

Re: DTS Standard and Protection Profile for Connected Diabetes Device Security (DTSec)

Re: DTS Standard and Protection Profile for Connected Diabetes Device Security (DTSec) 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org February 11, 2016 David Klonoff, MD, FACP, FRCP President Diabetes Technology Society

More information

Recent Developments in FDA s Review of Proprietary Names for Drugs

Recent Developments in FDA s Review of Proprietary Names for Drugs Recent Developments in FDA s Review of Proprietary Names for Drugs Kellie Taylor, PharmD, MPH Deputy Director Office of Medication Error Prevention and Risk Management, CDER Division Director (acting)

More information

POLICY AND PROCEDURES OFFICE OF SURVEILLANCE AND EPIDEMIOLOGY. Procedures for Handling Requests for Proprietary Name Review.

POLICY AND PROCEDURES OFFICE OF SURVEILLANCE AND EPIDEMIOLOGY. Procedures for Handling Requests for Proprietary Name Review. POLICY AND PROCEDURES OFFICE OF SURVEILLANCE AND EPIDEMIOLOGY Procedures for Handling Requests for Proprietary Name Review Table of Contents PURPOSE...1 BACKGROUND...1 POLICY...2 RESPONSIBILITIES AND PROCEDURES...3

More information

Design Considerations and Premarket. Recommendations for Interoperable Medical Devices Guidance for Industry and Food and Drug Administration Staff

Design Considerations and Premarket. Recommendations for Interoperable Medical Devices Guidance for Industry and Food and Drug Administration Staff Design Considerations and Premarket Submission Recommendations for Interoperable Medical Devices Guidance for Industry and Food and Drug Administration Staff Document issued on: September 6, 2017 The draft

More information

Article. Reference. Usability Validation of Medical Devices: Issues in Identifying Potential Use Errors. SCHIRO, Jessica, et al.

Article. Reference. Usability Validation of Medical Devices: Issues in Identifying Potential Use Errors. SCHIRO, Jessica, et al. Article Usability Validation of Medical Devices: Issues in Identifying Potential Use Errors SCHIRO, Jessica, et al. Abstract In order to prevent use errors with their medical devices, manufacturers have

More information

DEPARTMENT OF HEALTH & HUMAN SERVICES

DEPARTMENT OF HEALTH & HUMAN SERVICES DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 March 22, 2016 Tara M. Federici, Vice President Zachary A. Rothstein,

More information

Use of Standards and Conformity Assessment in U.S. Regulation: Perspective of the Private Sector

Use of Standards and Conformity Assessment in U.S. Regulation: Perspective of the Private Sector Use of Standards and Conformity Assessment in U.S. Regulation: Perspective of the Private Sector Standards Alliance Peru Workshop on Regulatory Decision Making October 29-30, 2014 Presentation Objectives

More information

Conference for Food Protection. Standards for Accreditation of Food Protection Manager Certification Programs. Frequently Asked Questions

Conference for Food Protection. Standards for Accreditation of Food Protection Manager Certification Programs. Frequently Asked Questions Conference for Food Protection Standards for Accreditation of Food Protection Manager Certification Programs Frequently Asked Questions Q. What was the primary purpose for the Conference for Food Protection

More information

OPG Comments on REGDOC-1.1.5, Licence Application Guide: Small Modular Reactor Facilities

OPG Comments on REGDOC-1.1.5, Licence Application Guide: Small Modular Reactor Facilities From: TRAIN David -NUCLEAR [mailto:david.train@opg.com] Sent: September-25-18 2:51 PM To: Consultation (CNSC/CCSN) Cc: MANLEY Robin -NUCLEAR; KHAN Saad -NUCLEAR Subject: OPG Comments on REGDOC-1.1.5, Licence

More information

Re: Docket No. FDA-2011-D Draft Guidance for Industry and Food and Drug Administration Staff; Mobile Medical Applications

Re: Docket No. FDA-2011-D Draft Guidance for Industry and Food and Drug Administration Staff; Mobile Medical Applications 701 Pennsylvania Avenue, Ste. 800 Washington, DC 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org October 19, 2011 Division of Dockets Management (HFA-305) Food and Drug Administration 5630

More information

LNE/G-MED North America, Inc

LNE/G-MED North America, Inc LNE/G-MED North America, Inc Medical Device Usability: Highlights of European Regulations and the Latest Standards Do not distribute or reproduce without permission 1 Sara Jafari, Ph.D., Medical Device

More information

FDA CDRH perspective on new technologies in inhaler products

FDA CDRH perspective on new technologies in inhaler products 2017 IPAC RS/ISAM Joint Workshop New Frontiers in Inhalation Technology FDA CDRH perspective on new technologies in inhaler products Linda Ricci Associate Director ODE DH Office of Device Evaluation Center

More information

26 February Office of the Secretary Public Company Accounting Oversight Board 1666 K Street, NW Washington, DC

26 February Office of the Secretary Public Company Accounting Oversight Board 1666 K Street, NW Washington, DC 3701 Algonquin Road, Suite 1010 Telephone: 847.253.1545 Rolling Meadows, Illinois 60008, USA Facsimile: 847.253.1443 Web Sites: www.isaca.org and www.itgi.org 26 February 2007 Office of the Secretary Public

More information

Applying Human Factors to Medical Device Design

Applying Human Factors to Medical Device Design Applying Human Factors to Medical Device Design Standards and Guidelines MEDEC 2016 Tim Reeves, PhD CHFP About Tim Reeves Founder and Managing Director of Human Factors MD Inc. Ten- person human factors

More information

International Pharmaceutical Aerosol Consortium on Regulation and Science

International Pharmaceutical Aerosol Consortium on Regulation and Science International Pharmaceutical Aerosol Consortium on Regulation and Science 1500 K Street NW Washington DC 20005 Telephone +1 202 230 5607 Fax +1 202 842 8465 Email info@ipacrs.org Web www.ipacrs.org August

More information

Common Statistical Analysis Plan (SAP) Frequently Asked Questions

Common Statistical Analysis Plan (SAP) Frequently Asked Questions Last Updated 4-Nov-2018 Topics 1 Stakeholder Input to Common SAP Template Development... 2 2 Template Content... 2 3 Implementation of the Common SAP template by the Sponsor... 55 4 Updates to the Common

More information

AAMI Sterilization Standards Week FDA Co-Chair Update: Transitions Spring 2017

AAMI Sterilization Standards Week FDA Co-Chair Update: Transitions Spring 2017 AAMI Sterilization Standards Week FDA Co-Chair Update: Transitions Spring 2017 Sharon Lappalainen Deputy Director, CDRH Standards Program Center for Devices and Radiological Health Office of the Center

More information

Policy for Accrediting Assessment Bodies Operating within the Cradle to Cradle Certified Product Certification Scheme. Version 1.2

Policy for Accrediting Assessment Bodies Operating within the Cradle to Cradle Certified Product Certification Scheme. Version 1.2 Policy for Accrediting Assessment Bodies Operating within the Cradle to Cradle Certified Product Certification Scheme Version 1.2 July 2015 Copyright, Cradle to Cradle Products Innovation Institute, 2015

More information

USA HEAD OFFICE 1818 N Street, NW Suite 200 Washington, DC 20036

USA HEAD OFFICE 1818 N Street, NW Suite 200 Washington, DC 20036 US-China Business Council Comments on The Draft Measures for Security Review of Online Products and Services March 6, 2017 On behalf of the more than 200 members of the US-China Business Council (USCBC),

More information

CERTIFICATE SCHEME THE MATERIAL HEALTH CERTIFICATE PROGRAM. Version 1.1. April 2015

CERTIFICATE SCHEME THE MATERIAL HEALTH CERTIFICATE PROGRAM. Version 1.1. April 2015 CERTIFICATE SCHEME For THE MATERIAL HEALTH CERTIFICATE PROGRAM Version 1.1 April 2015 Copyright Cradle to Cradle Products Innovation Institute, 2015 1 Purpose The intention of the Certificate Scheme is

More information

THINK THE FDA DOESN T CARE ABOUT USER EXPERIENCE FOR MOBILE MEDICAL APPLICATIONS? THINK AGAIN.

THINK THE FDA DOESN T CARE ABOUT USER EXPERIENCE FOR MOBILE MEDICAL APPLICATIONS? THINK AGAIN. THINK THE FDA DOESN T CARE ABOUT USER EXPERIENCE FOR MOBILE MEDICAL APPLICATIONS? THINK AGAIN. When granting regulatory approvals for medical devices, both IEC 62366 and the FDA have emphasized the importance

More information

University of Pennsylvania Institutional Review Board

University of Pennsylvania Institutional Review Board Reliance Agreement Guidance Creating Consent Templates This document provides step by step guidance on how to convert the Penn IRB approved consent form into a consent form template that can be shared

More information

International Auditing and Assurance Standards Board (IAASB) International Federation of Accountants 545 Fifth Avenue, 14 th Floor New York, NY 10017

International Auditing and Assurance Standards Board (IAASB) International Federation of Accountants 545 Fifth Avenue, 14 th Floor New York, NY 10017 3701 Algonquin Road, Suite 1010 Telephone: 847.253.1545 Rolling Meadows, Illinois 60008, USA Facsimile: 847.253.1443 Web Sites: www.isaca.org and www.itgi.org 25 April 2008 International Auditing and Assurance

More information

!"# $ # # $ $ % $ &% $ '"# $ ()&*&)+(( )+(( )

!# $ # # $ $ % $ &% $ '# $ ()&*&)+(( )+(( ) !"# # # % &% '"# ) !#, ' "# " "# -. / # 0 0 0 0 0 "0 "# " # 1 #! " " 0 0 0 0 0 0 2# 0 # # 3 ' 4 56 7-56 87 9# 5 6 7 6 & 0 " : 9 ; 4 " #! 0 - '% # % "# " "# " < 4 "! % " % 4 % % 9# 4 56 87 = 4 > 0 " %!#

More information

Comments on the Draft Policy Statement PS-ANE published online for public comment at

Comments on the Draft Policy Statement PS-ANE published online for public comment at Certification Project Notification (CPN) Submittal for Parts Manufacturer Approvals (PMAs) of Propeller Parts with a Failure Mode that could Result in the Total Loss of Thrust Comments on the Draft Policy

More information

FDA Finalizes Regulation Amending Food Facility Registration Regulations

FDA Finalizes Regulation Amending Food Facility Registration Regulations Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 T +1 202 637 5600 F +1 202 637 5910 www.hoganlovells.com MEMORANDUM From: Joseph A. Levitt Maile Gradison Hermida Elizabeth

More information

Common Protocol Template (CPT) Frequently Asked Questions

Common Protocol Template (CPT) Frequently Asked Questions Last Updated 12-December-2017 Topics 1 Rationale for Using the CPT... 2 2 Stakeholder Input to CPT Development... 3 3 Alignment of CPT and National Institutes of Health (NIH) Food and Drug Administration

More information

FDA Initiatives on Human Factors and Usability for Medical Devices Molly Follette Story, PhD FDA /CDRH / ODE

FDA Initiatives on Human Factors and Usability for Medical Devices Molly Follette Story, PhD FDA /CDRH / ODE FDA Initiatives on Human Factors and Usability for Medical Devices Molly Follette Story, PhD FDA /CDRH / ODE 2011 AMIA Pre-Symposium Washington, DC October 21, 2011 1 2 3 Regulatory Basis for HF at FDA

More information

Off-label unsolicited requests How to respond?

Off-label unsolicited requests How to respond? Off-label unsolicited requests How to Due to the rapid growth of the internet and social media tools, it is easier for both consumers and healthcare professionals to quickly seek information about medical

More information

Office of Human Research

Office of Human Research Office of Human Research JeffTrial End-User Training Document Regulatory Coordinator Training for Non-Oncology personnel Office of Human Research 8/16/2013 Ver. 1.0 Contents The REG Role: Completing Basic

More information

Standards: Implementation, Certification and Testing Work group Friday, May 8, :00 Pm-1:30 Pm ET.

Standards: Implementation, Certification and Testing Work group Friday, May 8, :00 Pm-1:30 Pm ET. Standards: Implementation, Certification and Testing Work group Friday, May 8, 2015. 12:00 Pm-1:30 Pm ET. Agenda Complete Work group Comments- Group 1 Review Group 2 Comments. 2015 Edition Certification

More information

MEDICAL DEVICE CYBERSECURITY: FDA APPROACH

MEDICAL DEVICE CYBERSECURITY: FDA APPROACH MEDICAL DEVICE CYBERSECURITY: FDA APPROACH CYBERMED SUMMIT JUNE 9TH, 2017 SUZANNE B. SCHWARTZ, MD, MBA ASSOCIATE DIRECTOR FOR SCIENCE & STRATEGIC PARTNERSHIPS CENTER FOR DEVICES AND RADIOLOGICAL HEALTH

More information

pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Expert Review Committee Initial Recommendation

pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Expert Review Committee Initial Recommendation pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Expert Review Committee Initial Recommendation Avelumab (Bavencio) for metastatic Merkel Cell Carcinoma March 21, 2018 3 Feedback on perc

More information

April 25, Dear Secretary Sebelius,

April 25, Dear Secretary Sebelius, April 25, 2014 Department of Health and Human Services Office of the National Coordinator for Health Information Technology Attention: 2015 Edition EHR Standards and Certification Criteria Proposed Rule

More information

2013, Healthcare Intelligence Network

2013, Healthcare Intelligence Network Note: This is an authorized excerpt from 2013 Healthcare Benchmarks: Mobile Health. To download the entire report, go to http://store.hin.com/product.asp?itemid=4586 or call 888-446-3530. 2013, Healthcare

More information

Medical Device Cybersecurity: FDA Perspective

Medical Device Cybersecurity: FDA Perspective Medical Device Cybersecurity: FDA Perspective Suzanne B. Schwartz MD, MBA Associate Director for Science and Strategic Partnerships Office of the Center Director (OCD) Center for Devices and Radiological

More information

Virginia State University Policies Manual. Title: Information Security Program Policy: 6110

Virginia State University Policies Manual. Title: Information Security Program Policy: 6110 Purpose Virginia State University (VSU) uses information to perform the business services and functions necessary to fulfill its mission. VSU information is contained in many different mediums including

More information

Acceptance Checklist for Special 510(k)

Acceptance Checklist for Special 510(k) Acceptance Checklist for Special 510(k)s (should be completed within 15 days of DCC receipt) The following information is not intended to serve as a comprehensive review. 510(k) Number: Date Received by

More information

Purpose: To describe the requirements for managing IP at the clinical site

Purpose: To describe the requirements for managing IP at the clinical site Title: Investigational Product Management Topic: Management of IP Effective Date: March 16, 2016 Approved By: Rita Hanson, M.D. Senior VP/Chief Medical Officer Purpose: To describe the requirements for

More information

Exploring the Maturity of Risk Management Process in Government: An Integrated ERM Model at the U.S. Department of Education

Exploring the Maturity of Risk Management Process in Government: An Integrated ERM Model at the U.S. Department of Education Exploring the Maturity of Risk Management Process in Government: An Integrated ERM Model at the U.S. Department of Education FEDERAL STUDENT AID ENTERPRISE RISK MANAGEMENT GROUP Cynthia Vitters 1. ERM

More information

Medical Device Usability

Medical Device Usability Medical Device Usability David Adams Global Head, Active Medical Devices Add logo on slide 4 here Topics What is usability? Why usability is so important The regulatory requirements EN 62366 Usability

More information

ABB Limited. Table of Content. Executive Summary

ABB Limited. Table of Content. Executive Summary 21 CFR Part 11 Electronic Records; Electronic Signatures Guidance for Industry Scope of Application Position Paper: A Summary and Interpretation of the Guidance Note: This document has been prepared based

More information

Reviewers Guide on Clinical Trials

Reviewers Guide on Clinical Trials Reviewers Guide on Clinical Trials Office of Research Integrity & Compliance Version 2 Updated: June 26, 2017 This document is meant to help board members conduct reviews for Full Board: Clinical Trial

More information

IQ Level 4 Award in Understanding the External Quality Assurance of Assessment Processes and Practice (QCF) Specification

IQ Level 4 Award in Understanding the External Quality Assurance of Assessment Processes and Practice (QCF) Specification IQ Level 4 Award in Understanding the External Quality Assurance of Assessment Processes and Practice (QCF) Specification Regulation No: 600/5528/5 Page 1 of 15 Contents Page Industry Qualifications...

More information

WELCOME. October 19, 2017 The Mandarin Oriental Washington, DC

WELCOME. October 19, 2017 The Mandarin Oriental Washington, DC WELCOME October 19, 2017 The Mandarin Oriental Washington, DC Schedule of Events 5:30 7:00 pm Cocktail Reception 6:40 7:10 pm Music USPHS Brass Ensemble 7:00 8:00 pm Welcome Remarks Master of Ceremonies

More information

Implementation of UDI In the Medical Device Industry

Implementation of UDI In the Medical Device Industry Implementation of UDI In the Medical Device Industry IMDRF UDI Workshop - Brussels, Belgium Monday, 12 February 2018 Jackie Rae Elkin - Global Medical Technology Alliance (GMTA) James Turner - Global Diagnostic

More information

Topics Raised by EFPIA. Webinar on Policy Jun 2017, FINAL. Presentation

Topics Raised by EFPIA. Webinar on Policy Jun 2017, FINAL. Presentation Topics Raised by EFPIA Webinar on Policy 70 29 Jun 2017, FINAL Presentation Definition of listings out of scope of Phase 1 Examples Topics to discuss Previously submitted studies in scope Reiterating EFPIA

More information

Copyright 2018 by Boston Scientific, Inc.. Permission granted to INCOSE to publish and use. #hwgsec

Copyright 2018 by Boston Scientific, Inc.. Permission granted to INCOSE to publish and use. #hwgsec Balancing Safety, Security and Usability in the Design of Secure Medical Devices Ken Hoyme Director, Product Security Boston Scientific Ken.hoyme@bsci.com Copyright 2018 by Boston Scientific, Inc.. Permission

More information

Issue for Consideration: Appropriateness of the Drafting of Paragraph A17

Issue for Consideration: Appropriateness of the Drafting of Paragraph A17 Deloitte & Touche LLP Ten Westport Road Wilton, CT 06897-0820 USA Tel: +1 203 761 3000 Fax: +1 203 761 3013 www.deloitte.com Sherry Hazel Audit and Attest Standards American Institute of Certified Public

More information

National Research Council of Canada 2006 Safety Codes Council 2010 (Alberta specific intent and application statements)

National Research Council of Canada 2006 Safety Codes Council 2010 (Alberta specific intent and application statements) Disclaimer This guide was created through funding provided by the Safety Codes Council and Alberta Municipal Affairs. The intent and application statements contained within this guide provide useful explanatory

More information

pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Expert Review Committee Initial Recommendation (Manufacturer)

pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Expert Review Committee Initial Recommendation (Manufacturer) pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Expert Review Committee Initial Recommendation (Manufacturer) Blinatumomab (Blincyto) for Philadelphia chromosome positive Acute Lymphoblastic

More information

Requirements on clinical data in Europe

Requirements on clinical data in Europe Requirements on clinical data in Europe Dr. Bassil Akra Director Global Clinical Affairs TÜV SÜD Product Service Current Medical Device Directives Applicable Directives Active Implantable Medical Devices

More information

TaiHao Medical Inc. Chiu S. Lin, Ph.D. President Lin & Associates, LLC 5614 Johnson Avenue BETHESDA MD 20817

TaiHao Medical Inc. Chiu S. Lin, Ph.D. President Lin & Associates, LLC 5614 Johnson Avenue BETHESDA MD 20817 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Chiu S. Lin, Ph.D. President

More information

Unique Device Identification (UDI) Status, Learnings, Next Steps

Unique Device Identification (UDI) Status, Learnings, Next Steps Unique Device Identification (UDI) Status, Learnings, Next Steps Jeffrey Shuren, M.D., J.D. Center for Devices and Radiological Health (CDRH) US Food and Drug Administration (FDA) IMDRF September 2016

More information

Medical Device Vulnerability Management

Medical Device Vulnerability Management Medical Device Vulnerability Management MDISS / NH-ISAC Process Draft Dale Nordenberg, MD June 2015 Market-based public health: collaborative acceleration Objectives Define a trusted and repeatable process

More information

Suzanne B. Schwartz, MD, MBA Director Emergency Preparedness/Operations & Medical Countermeasures (EMCM Program) CDRH/FDA

Suzanne B. Schwartz, MD, MBA Director Emergency Preparedness/Operations & Medical Countermeasures (EMCM Program) CDRH/FDA Preventing the Unthinkable: Issues in MedTech Cyber Security Trends and Policies MassMEDIC Cambridge, Mass Thursday Oct 1, 2015 Suzanne B. Schwartz, MD, MBA Director Emergency Preparedness/Operations &

More information

ACCREDITATION COMMISSION FOR CONFORMITY ASSESSMENT BODIES

ACCREDITATION COMMISSION FOR CONFORMITY ASSESSMENT BODIES ACCREDITATION COMMISSION FOR CONFORMITY ASSESSMENT BODIES ACCREDITATION SCHEME MANUAL Document Title: Document Number: Various Accreditation Schemes ACCAB-ASM-7.0 CONTROLLED COPY Revision Number Revision

More information

POSTMARKET MANAGEMENT OF CYBERSECURITY IN MEDICAL DEVICES FINAL GUIDANCE MARCH 29, TH ANNUAL MEDICAL DEVICE QUALITY CONGRESS

POSTMARKET MANAGEMENT OF CYBERSECURITY IN MEDICAL DEVICES FINAL GUIDANCE MARCH 29, TH ANNUAL MEDICAL DEVICE QUALITY CONGRESS POSTMARKET MANAGEMENT OF CYBERSECURITY IN MEDICAL DEVICES FINAL GUIDANCE MARCH 29, 2017 14TH ANNUAL MEDICAL DEVICE QUALITY CONGRESS 1 Fact vs. Myth Let s Play: Fact vs. Myth The FDA is the federal entity

More information

IEC/TR : (E)

IEC/TR : (E) IEC/TR 62366-2:2016-04 (E) Medical devices - Part 2: Guidance on the application of usability engineering to medical devices Contents Page FOREWORD... 6 INTRODUCTION... 8 1 Scope and purpose... 9 1.1 Scope...

More information

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA UNITED STATES OF AMERICA, v. Plaintiff, MICROSOFT CORPORATION, Civil Action No. 98-1232 (CKK) Next Court Deadline: May 12, 2006 Joint Status

More information

APPROVAL FCA103 ISSUED BY THE COMPETENT AUTHORITY OF THE UNITED STATES EXPIRATION DATE: March 31, 2019

APPROVAL FCA103 ISSUED BY THE COMPETENT AUTHORITY OF THE UNITED STATES EXPIRATION DATE: March 31, 2019 U.S. Department East Building, PHH 32 of Transportation 1200 New Jersey Avenue, Southeast Pipeline and Hazardous Materials Safety Administration Washington, D.C. 20590 APPROVAL FCA103 ISSUED BY THE COMPETENT

More information

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office SOP 1027 LU

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office SOP 1027 LU LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1027 LU Process for Writing Study Protocols for NHS Research Sponsored by Loughborough

More information

ACCREDITATION COMMISSION FOR CONFORMITY ASSESSMENT BODIES

ACCREDITATION COMMISSION FOR CONFORMITY ASSESSMENT BODIES ACCREDITATION COMMISSION FOR CONFORMITY ASSESSMENT BODIES ACCREDITATION SCHEME MANUAL Document Title: Document Number: Various Accreditation Schemes ACCAB-ASM-7.0 CONTROLLED COPY Revision Number Revision

More information

February 18, The Honorable Kimberly D. Bose Secretary Federal Energy Regulatory Commission 888 First Street, NE Washington, DC 20426

February 18, The Honorable Kimberly D. Bose Secretary Federal Energy Regulatory Commission 888 First Street, NE Washington, DC 20426 California Independent System Operator Corporation February 18, 2015 The Honorable Kimberly D. Bose Secretary Federal Energy Regulatory Commission 888 First Street, NE Washington, DC 20426 Re: California

More information

What is Usability? What is the Current State? Role and Activities of NIST in Usability Reactions from Stakeholders What s Next?

What is Usability? What is the Current State? Role and Activities of NIST in Usability Reactions from Stakeholders What s Next? What is Usability? What is the Current State? Role and Activities of NIST in Usability Reactions from Stakeholders What s Next? Usability is "the extent to which a product can be used by specified users

More information

Request for Comments (RFC) Process Guide

Request for Comments (RFC) Process Guide PAYMENT CARD INDUSTRY SECURITY STANDARDS COUNCIL Request for Comments (RFC) Process Guide VERSION 1.0 FEBRUARY 2019 Purpose of this Guide Request for comment (RFC) periods are avenues for PCI SSC stakeholders

More information

1717 Pennsylvania Avenue, N.W. 12 th Floor Washington, D.C November 6, 2014

1717 Pennsylvania Avenue, N.W. 12 th Floor Washington, D.C November 6, 2014 1717 Pennsylvania Avenue, N.W. 12 th Floor Washington, D.C. 20006 Tel 202 659 6600 Fax 202 659-6699 www.eckertseamans.com James C. Falvey jfalvey@eckertseamans.com Phone: 202 659-6655 Notice of Ex Parte

More information

The National Medical Device Information Sharing & Analysis Organization (MD-ISAO) Initiative Session 2, February 19, 2017 Moderator: Suzanne

The National Medical Device Information Sharing & Analysis Organization (MD-ISAO) Initiative Session 2, February 19, 2017 Moderator: Suzanne The National Medical Device Information Sharing & Analysis Organization (MD-ISAO) Initiative Session 2, February 19, 2017 Moderator: Suzanne Schwartz, Assoc. Dir., CDRH, FDA Denise Anderson, MBA, President,

More information

2018. All rights reserved.

2018. All rights reserved. DOCUMENT: Future AAMI/IEC 62366-1:2015/Amendment 1, Medical devices Application of usability Engineering to medical devices Amendment 1 Public Review Draft Designation: AAMI/CDV-2 62366-1:2015/DAmd 1 AAMI

More information

JUST WHAT THE DOCTOR ORDERED: A SOLUTION FOR SMARTER THERAPEUTIC DEVICES PLACEHOLDER IMAGE INNOVATORS START HERE.

JUST WHAT THE DOCTOR ORDERED: A SOLUTION FOR SMARTER THERAPEUTIC DEVICES PLACEHOLDER IMAGE INNOVATORS START HERE. JUST WHAT THE DOCTOR ORDERED: A SOLUTION FOR SMARTER THERAPEUTIC DEVICES PLACEHOLDER IMAGE INNOVATORS START HERE. EXECUTIVE SUMMARY There s little question that advances in therapeutic technologies have

More information

HUMAN CENTERED DESIGN

HUMAN CENTERED DESIGN HUMAN CENTERED DESIGN Ed Israelski PhD CHFP, Convener of Usability and Ergonomics Working Groups IEC/ISO Retired Director Human Factors, AbbVie Past Co-Chair HFE Committee, AAMI HFE Consultant Roundtable

More information

GUIDE 63. Guide to the development and inclusion of safety aspects in International Standards for medical devices

GUIDE 63. Guide to the development and inclusion of safety aspects in International Standards for medical devices GUIDE 63 Guide to the development and inclusion of safety aspects in International Standards for medical devices Second edition 2012 ISO/IEC 2012 ISO/IEC GUIDE 63:2012(E) This is a preview - click here

More information

ITG. Information Security Management System Manual

ITG. Information Security Management System Manual ITG Information Security Management System Manual This manual describes the ITG Information Security Management system and must be followed closely in order to ensure compliance with the ISO 27001:2005

More information

HTA for Medical Devices. Pascale Brasseur Health Economics & Reimbursement Director, Cardiovascular, Medtronic International Sa

HTA for Medical Devices. Pascale Brasseur Health Economics & Reimbursement Director, Cardiovascular, Medtronic International Sa HTA for Medical Devices Pascale Brasseur Health Economics & Reimbursement Director, Cardiovascular, Medtronic International Sa Agenda A few figures on Medical Devices Frequency of HTAs performed on Medical

More information

REPORT 2015/149 INTERNAL AUDIT DIVISION

REPORT 2015/149 INTERNAL AUDIT DIVISION INTERNAL AUDIT DIVISION REPORT 2015/149 Audit of the information and communications technology operations in the Investment Management Division of the United Nations Joint Staff Pension Fund Overall results

More information

Examining Rescue Studies

Examining Rescue Studies White Paper Examining Rescue Studies Introduction The purpose of this White Paper is to define a Rescue Study, outline the basic assumptions, including risks, in setting up such a trial based on DATATRAK

More information

OFFICE OF THE UNDER SECRETARY OF DEFENSE 3000DEFENSEPENTAGON WASHINGTON, DC

OFFICE OF THE UNDER SECRETARY OF DEFENSE 3000DEFENSEPENTAGON WASHINGTON, DC OFFICE OF THE UNDER SECRETARY OF DEFENSE 3000DEFENSEPENTAGON WASHINGTON, DC 20301-3000 ACQUISITION, TECHNO LOGY. A N D LOGISTICS SEP 2 1 2017 MEMORANDUM FOR COMMANDER, UNITED ST A TES SPECIAL OPERATIONS

More information

Comment sheet for MHRA draft document:

Comment sheet for MHRA draft document: Comment sheet for MHRA draft document: MHRA GxP Data Integrity Definitions and Guidance for Industry Deadline for comments: 31 October 2016 Send comments in Word format to: inspectorate@mhra.gsi.gov.uk

More information

Agency Information Collection Activities: Proposed Collection; Comment Request

Agency Information Collection Activities: Proposed Collection; Comment Request This document is scheduled to be published in the Federal Register on 06/06/2016 and available online at http://federalregister.gov/a/2016-13289, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES

More information

Overview of updates to PAG Activities 1 st February 2016

Overview of updates to PAG Activities 1 st February 2016 Overview of updates to PAG Activities 1 st February 2016 Please find below a centralised copy of the sections of the Chemistry PAG Activities sheets as a quick reference to current versions and the changes

More information

January 16, Re: Request for Comment: Data Access and Data Sharing Policy. Dear Dr. Selby:

January 16, Re: Request for Comment: Data Access and Data Sharing Policy. Dear Dr. Selby: Dr. Joe V. Selby, MD, MPH Executive Director Patient-Centered Outcomes Research Institute 1828 L Street, NW, Suite 900 Washington, DC 20036 Submitted electronically at: http://www.pcori.org/webform/data-access-and-data-sharing-policypublic-comment

More information

CENTRAL OREGON COMMUNITY COLLEGE CAMPUS CLIMATE SURVEY

CENTRAL OREGON COMMUNITY COLLEGE CAMPUS CLIMATE SURVEY CENTRAL OREGON COMMUNITY COLLEGE CAMPUS CLIMATE SURVEY 2005, 2007, 2009, 2011 and 2013 The Campus Climate Survey is administered by the Organizational Development Committee every other year. The survey

More information

STATE OF NORTH CAROLINA OFFICE OF THE STATE AUDITOR BETH A. WOOD, CPA FAYETTEVILLE STATE UNIVERSITY

STATE OF NORTH CAROLINA OFFICE OF THE STATE AUDITOR BETH A. WOOD, CPA FAYETTEVILLE STATE UNIVERSITY STATE OF NORTH CAROLINA OFFICE OF THE STATE AUDITOR BETH A. WOOD, CPA FAYETTEVILLE STATE UNIVERSITY INFORMATION TECHNOLOGY GENERAL CONTROLS INFORMATION SYSTEMS AUDIT JANUARY 2016 EXECUTIVE SUMMARY PURPOSE

More information